Clinical Trials Directory

Trials / Completed

CompletedNCT02657161

Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
37 (actual)
Sponsor
Yisheng Biopharma (Singapore) Pte. Ltd. · Industry
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

Phase I clinical study for an investigational PIKA (Polyinosinic-Polycytidylic Acid Based Adjuvant) rabies vaccine comprising Inactivated and Purified Rabies Virus (IPRV) and the PIKA adjuvant. The primary objective of the study was to assess the clinical safety of the vaccine composition in healthy adult volunteers. The secondary objective was to evaluate the vaccine's efficacy based on an accelerated vaccine regimen.

Detailed description

A single-center, open label, randomized phase I study in healthy naïve adult subjects. There were three study groups; subjects were randomly assigned to groups A (12), B (12) and C (12). Group A, as a control arm of the study, had received a commercially available rabies vaccine, RABIPUR® and Group B had received doses of the investigational PIKA rabies vaccine. Group C received an accelerated vaccine regimen with the investigational PIKA rabies vaccine. Group A and B followed the same vaccine regimen of (1-1-1-1), one injection on days 0, 3, 7 and 14 was administered respectively. Group C received the accelerated regimen (2-2-1), two injections on both days 0 and 3 were administered in different arms; and only one injection was administered on day 7. Each vaccine dose comprise 1.0 ml of PIKA rabies vaccine for Group B and Group C and 1.0 ml of RABIPUR® for Group A after reconstitution. The route of administration is intramuscular injection, given in the deltoid region of the arm.

Conditions

Interventions

TypeNameDescription
BIOLOGICALRABIPUR®Biological rabies vaccine
BIOLOGICALPIKA rabies vaccineBiological rabies vaccine
BIOLOGICALPIKA rabies vaccine with an accelerated regimenBiological rabies vaccine

Timeline

Start date
2015-02-01
Primary completion
2015-07-01
Completion
2015-07-01
First posted
2016-01-15
Last updated
2016-01-15

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT02657161. Inclusion in this directory is not an endorsement.